This test measures the amount of BCR-ABL fusion gene in a patient's blood or bone marrow by detecting and quantifying the BCR-ABL mRNA.
The BCR-ABL RT-PCR Quantitative Test is a critical diagnostic and monitoring tool primarily used for individuals diagnosed with Chronic Myelogenous Leukemia (CML) and other Philadelphia chromosome-positive (Ph+) leukemias.The presence of this abnormal fusion gene, which results from a translocation between chromosomes 9 and 22 (known as the Philadelphia chromosome), is a hallmark of CML and certain types of acute lymphoblastic leukemia (ALL).
The BCR-ABL RT-PCR Quantitative Test is used for several key purposes in the management of CML and Ph+ ALL:
1] Diagnosis: The test confirms the presence of the Philadelphia chromosome in patients suspected of having CML or Ph+ ALL. The BCR-ABL fusion gene is found in nearly all patients with CML, making it a critical diagnostic marker.
2] Monitoring Treatment Response: The test helps evaluate how well a patient is responding to targeted therapy (such as imatinib or other tyrosine kinase inhibitors). These therapies are designed to block the activity of the BCR-ABL protein, and the RT-PCR test quantifies how much BCR-ABL mRNA remains in the patient’s blood, indicating whether the leukemia is being controlled effectively.
3] Assessing Minimal Residual Disease (MRD): Even when CML patients achieve complete cytogenetic remission (meaning no detectable Philadelphia chromosome in their cells), small amounts of the BCR-ABL gene may still remain. This is called minimal residual disease (MRD). The quantitative RT-PCR test can detect very low levels of BCR-ABL mRNA, helping doctors identify if any disease remains and if adjustments to treatment are needed.
4] Detecting Relapse or Resistance: If the BCR-ABL mRNA levels start to rise during treatment, it may indicate relapse or treatment resistance. Monitoring these levels is essential for detecting early signs of resistance to therapy, allowing doctors to adjust treatment plans accordingly.
5] Prognostication: The quantity of BCR-ABL mRNA detected can also be used to predict the patient's long-term prognosis. Higher levels of BCR-ABL often correlate with more aggressive disease or poorer outcomes, while lower levels may indicate better control of the leukemia.
1] Low or Undetectable Levels: Low or undetectable BCR-ABL levels often indicate that the leukemia is in remission or well-controlled by therapy.
2] Intermediate or High Levels: Elevated BCR-ABL levels suggest active disease and may require a change in therapy, especially if resistance to treatment is suspected.
3] BCR-ABL Major Molecular Response (MMR): A significant reduction in BCR-ABL levels (usually defined as a 3-log reduction from baseline) is considered a Major Molecular Response (MMR), a desirable outcome in CML treatment.
At Diagnopein, we offer comprehensive, accurate, and timely diagnostic services, including the BCR-ABL RT-PCR Quantitative Test Pune. With our NABL-accredited labs, cutting-edge technology, and skilled technicians, you can be assured of reliable results every time. Get your results quickly, especially when time is crucial in detecting severe infections.
Competitive pricing without compromising on quality. Our team of experienced professionals ensures the test is conducted smoothly with minimal discomfort. We provide not just the BCR-ABL RT-PCR Quantitative Test results but insights into your health condition, helping you and your doctor make informed decisions about treatment. For more information call us at +91 9204 108108.
A blood sample (or bone marrow in some cases) is collected and sent to a laboratory. In the lab, the BCR-ABL mRNA is converted into cDNA using reverse transcription, and then PCR is used to amplify the gene. The amount of BCR-ABL mRNA is quantified, typically in relation to a normal control gene (e.g., ABL1), to determine the level of the fusion gene.
The frequency of testing depends on the individual’s treatment plan and response to therapy. Initially, the test is often done every 3-6 months, but the frequency may decrease over time if the patient remains in remission. Regular monitoring helps detect relapse early and ensure continued effectiveness of treatment.
While the test is primarily used for CML and Ph+ ALL, it is also useful in monitoring treatment efficacy and relapse in other types of leukemia or cancers that involve the Philadelphia chromosome.
No, while the BCR-ABL RT-PCR test is essential for monitoring CML, other tests like bone marrow biopsy and cytogenetic analysis may also be used for initial diagnosis and to evaluate disease characteristics. The RT-PCR test is particularly useful for tracking disease progression and treatment response over time.
